Replies to post #201569 on Biotech Values

[genisi]

AGN does not have high hopes for DARPIN

I'm sure they did have high hopes and perhaps being more cautious after 2013. Still a decent chance in Ph3 for superior (up to 12wks) dosing. Worst case I expect is non inferior in efficacy and dosing and comparable inflammation rates. That of course would make it a "me too" kind of a drug. We'll know in two years...